Induction of such effectors would provide a possibility to strike virus infected cells via the MHC class II pathway and also to recognize and destroy macrophages that serve as a lengthy lived reservoir for HIV 1. Both volumes would demonstrably benefit a multiple component/multi gene HIV 1 vaccine. Conclusions We have shown that the agreement genes encoding inactivated HIV clade An integrase and natural product libraries its analog with key elvitegravir resistance variations are immunogenic for both B and T cells. We’ve described T cell immune response against the opinion integrase and discovered that it is executed by the CD4 T cells and polyfunctional CD8 co secreting IFN h, IL 2 and TNF a. As the potential to reduce local expression of the reporter gene co delivered with the IN gene immunogens we’ve indicated the operation of this immune response in the in vivo tests. The latter linked with the induction of IN particular result of polyfunctional CD8 and CD4 T cells with a phenotype, and was, for that reason, viewed as the immune mediated extermination of the expressing cells. Because it would provide a possibility to attack Infectious causes of cancer virus infected cells via both MHC class I and MHC class II pathways creation of such polyfunctional CD4 and CD8 T cell response is highly desirable for a fruitful HIV 1 vaccine. Creation of such polyfunctional T cells is highly desirable for a fruitful HIV 1 vaccine. Several new HIV 1 multigene vaccine trials have involved the IN gene,, which helps its perspectivity for immune treatment of HIV/AIDS, specifically, the reduction of drug resistance. Our opinion HIV 1 clade An immunogens could be especially designed to prevent epidemics caused by HIV 1 strains with reduced genetic diversity as within the Russian Federation,,. Crizotinib structure Methods Ethics Statement All tests were approved by the Northern Stockholm s Unit of the Ethics of Animal Research on 2010 08 26, moral permission N197/10 Evaluation of the new generation of vaccines against extremely dangerous contagious diseases and cancer. The studies communicated under this ethical choice aimed to produce new vaccines and new vaccination strategies against cancer and severe viral infections as HIV, and to advance new treatment protocol for further clinical applications. Vaccine individuals to test beneath the program involved naked DNA vaccines, proteins, peptides and viral vectors used with or without adjuvants. Immunization were allowed by intramuscular, subcutaneous and intradermal injections, inoculations with Biojector with or without electroporation, and nasal immunization with falls. All electroporation, biojections and treatments were made under the inhalation anesthesia with a combination of air and 1. 5 to three or four isofluorane.